Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
复制标题
旁路血管成形术血运重建调查 2 糖尿病 (BARI 2D) 试验中基线血脂控制。
DOI：
10.1111/j.1751-7141.2008.00014.x
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Orchard,TrevorJ
中科院分区：
文献类型：
--
作者：
Pambianco,Georgia;Lombardero,Manuel;Bittner,Vera;Forker,Alan;Kennedy,Frank;Krishnaswami,Ashok;Mooradian,ArshagD;Pop-Busui,Rodica;Rana,JamalS;Rodriguez,Annabelle;Steffes,Michael;Orchard,TrevorJ
In order to examine lipids, a major treatment parameter in those with diabetes and heart disease, the authors analyzed baseline data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. The study consisted of 2368 participants with type 2 diabetes and coronary artery disease from 49 sites in 6 countries (2295 provided lipid measurements). Fifty‐nine percent of participants had a low‐density lipoprotein (LDL) cholesterol level <100 mg/dL. Levels of total, LDL, and non–high‐density lipoprotein (HDL) cholesterol and triglycerides differed by age group (younger than 55, 55–64, and 65 years and older); they were lowest in those aged 65 years. Women had higher total, LDL, and non‐HDL cholesterol values. Education was associated with lower total, LDL, and non‐HDL cholesterol levels. LDL cholesterol and triglyceride values were lower in the United States and Canada. Adjustment for age, sex, education level, randomization year, and medication did not eliminate these differences. Geographic variation was seen and was not fully accounted for by demographic or treatment characteristics (allPvalues <.05).
